* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download PFIZER’S CENTERS FOR THERAPEUTIC INNOVATION (CTI) CTI:
Survey
Document related concepts
Adaptive immune system wikipedia , lookup
Vaccination wikipedia , lookup
Immune system wikipedia , lookup
Transmission (medicine) wikipedia , lookup
Neglected tropical diseases wikipedia , lookup
Innate immune system wikipedia , lookup
Adoptive cell transfer wikipedia , lookup
Globalization and disease wikipedia , lookup
Germ theory of disease wikipedia , lookup
Cancer immunotherapy wikipedia , lookup
Multiple sclerosis research wikipedia , lookup
Immunosuppressive drug wikipedia , lookup
Rheumatoid arthritis wikipedia , lookup
Molecular mimicry wikipedia , lookup
Psychoneuroimmunology wikipedia , lookup
Sjögren syndrome wikipedia , lookup
Transcript
PFIZER’S CENTERS FOR THERAPEUTIC INNOVATION (CTI) REQUEST FOR TRANSLATIONAL PROPOSALS FOR BIOTHERAPEUTIC TARGETS Proposal Deadline: May 16, 2014 CTI: an innovative Pfizer program that partners with leading academic medical centers and foundations nationwide to accelerate the translation of novel targets to the clinic. CTI’s goal is to identify new compounds and accelerate research and drug development from validated target to proof‐of‐mechanism in the clinic. A partnership with CTI includes collaborative use of Pfizer’s proprietary antibody drug discovery tools and technologies, broad publishing rights and significant financial awards in the form of milestone and royalty payments for successful programs. Therapeutic Areas of Interest: › Inflammation, autoimmunity, tissue remodeling, oncology, rare or genetic diseases, neuroscience, cardiovascular and metabolic diseases › In this call, CTI especially seeks new partnerships in immunoregulation in autoimmune disease and cancer to either harness the immune system for tumor eradication or, conversely, targeted therapies to provide selective immunosuppression or immunoregulation for autoimmune diseases › For cancer immunotherapy, this may involve mechanisms to target T Regulatory cells, myeloid suppressor cells or other immune augmentation strategies › For the treatment of autoimmune disease, we are interested in novel approaches to treat a variety of diseases associated with immune dysregulation, including proposals describing intervention points to drive the development of immunological tolerance and de novo generation and/or functional enhancement of T regulatory cells What We Look For: › Targets that are tractable with biologics (i.e. surface proteins, secreted proteins) Strong link from targeted pathway to disease Opportunity to address unmet medical need › Differentiators such as: Ability to elucidate path to proof-of-mechanism in humans Clinical differentiation opportunity via patient stratification, molecular signatures, genetic associations and biomarkers › Biologics for the treatment of rheumatoid arthritis and psoriasis are out of scope for this proposal. All researchers, clinicians and post-docs whose work meets these criteria are invited to apply. For more information about submitting a proposal, please contact Ece Auffarth, [email protected] Pfizer CTI 2013 © www.PfizerCTI.com